Natera, Inc. $NTRA Holdings Boosted by Jump Financial LLC

Key Points

• Jump Financial LLC increased its stake in Natera, Inc. by 241.2%, acquiring an additional 152,721 shares during the recent quarter, bringing its total ownership to 216,038 shares valued at approximately $30.55 million.
• Insider transactions revealed that CFO Michael Burkes Brophy sold 3,045 shares, while CEO Steven Leonard Chapman sold 6,111 shares, indicating a decrease in their ownership percentages of 4.45% and 3.30%, respectively.
• Natera reported a quarterly revenue of $546.6 million, which was a 32.2% increase year-over-year, although it missed the earnings expectations with an EPS of ($0.74).

Jump Financial LLC lifted its stake in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 241.2% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 216,038 shares of the medical research company's stock after acquiring an additional 152,721 shares during the period. Jump Financial LLC owned 0.16% of Natera worth $30,550,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in NTRA. Fulton Bank N.A. grew its holdings in Natera by 2.0% in the 1st quarter. Fulton Bank N.A. now owns 3,652 shares of the medical research company's stock valued at $516,000 after buying an additional 71 shares during the period. Compound Planning Inc. lifted its holdings in shares of Natera by 4.2% during the 1st quarter. Compound Planning Inc. now owns 1,914 shares of the medical research company's stock worth $271,000 after acquiring an additional 78 shares during the period. QRG Capital Management Inc. boosted its position in shares of Natera by 1.5% in the first quarter. QRG Capital Management Inc. now owns 5,417 shares of the medical research company's stock worth $766,000 after acquiring an additional 81 shares during the last quarter. Earned Wealth Advisors LLC grew its holdings in Natera by 5.0% in the first quarter. Earned Wealth Advisors LLC now owns 1,737 shares of the medical research company's stock valued at $246,000 after purchasing an additional 82 shares during the period. Finally, Bridges Investment Management Inc. grew its holdings in Natera by 5.5% in the first quarter. Bridges Investment Management Inc. now owns 1,676 shares of the medical research company's stock valued at $237,000 after purchasing an additional 87 shares during the period. Institutional investors and hedge funds own 99.90% of the company's stock.

Insiders Place Their Bets

In related news, insider John Fesko sold 678 shares of Natera stock in a transaction dated Thursday, August 14th. The shares were sold at an average price of $155.46, for a total value of $105,401.88. Following the sale, the insider directly owned 152,747 shares in the company, valued at $23,746,048.62. This trade represents a 0.44% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Gail Boxer Marcus sold 2,496 shares of the stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $133.17, for a total value of $332,392.32. Following the completion of the transaction, the director directly owned 5,763 shares of the company's stock, valued at $767,458.71. This trade represents a 30.22% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 58,705 shares of company stock worth $8,743,776. 5.63% of the stock is owned by company insiders.

Analyst Ratings Changes

NTRA has been the topic of a number of recent analyst reports. Evercore ISI raised shares of Natera to a "strong-buy" rating and set a $170.00 price target on the stock in a research note on Monday, July 28th. Piper Sandler reiterated an "overweight" rating and set a $220.00 price objective (up from $210.00) on shares of Natera in a research note on Monday, August 11th. Cowen reaffirmed a "buy" rating on shares of Natera in a research report on Friday, August 8th. UBS Group increased their target price on Natera from $211.00 to $218.00 and gave the company a "buy" rating in a research note on Friday, May 9th. Finally, Barclays reissued an "overweight" rating and set a $210.00 price target (up from $190.00) on shares of Natera in a research report on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating and seventeen have given a Buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $193.19.

Natera Stock Performance

Shares of NTRA stock traded up $3.24 on Tuesday, hitting $165.71. 1,012,175 shares of the stock traded hands, compared to its average volume of 1,605,587. The company's fifty day moving average is $154.70 and its 200 day moving average is $154.02. Natera, Inc. has a 1-year low of $110.57 and a 1-year high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The medical research company reported ($0.74) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.14). The company had revenue of $546.60 million for the quarter, compared to the consensus estimate of $476.84 million. Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.Natera's quarterly revenue was up 32.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.30) earnings per share. Natera has set its FY 2025 guidance at EPS. As a group, equities research analysts predict that Natera, Inc. will post -1.49 EPS for the current year.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.